Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Each year the Prostate Cancer Foundation gives out its “Creativity Awards” — intended to support research into new ideas with the potential to significantly affect the diagnosis and treatment of prostate cancer.
Filed under: Drugs in development | Tagged: anti-OX40, awards, Botox, creativity, metformin, research, TKI258 | Leave a Comment »
One of the unknown factors in the use of high-intensity focused ultrasound (HIFU) for the first-line treatment of prostate cancer is the potential for high-quality, biochemical recurrence-free survival over time. Post-treatment histopathology may offer some insight into the likelihood of good outcomes.
Filed under: Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound, histopathology, pathology | 9 Comments »
An article in the June issue of the Journal of Urology has suggested a definitive link between positive surgical margins (PSMs) post-surgery and prostate cancer-specific mortality (PCSM).
Filed under: Management, Treatment | Tagged: mortality, PCSM, positive surgical margins, PSM | Leave a Comment »
On May 6 this year, the President’s Cancer Panel issued its annual report for 2008-09, entitled Reducing Environmental Cancer Risk: What We Can Do Now. This report has stirred immediate controversy.
Filed under: Diagnosis, Prevention, Risk | Tagged: environment, risk | 6 Comments »
On May 11 we noted a report on the potential value of MRI scans in clinical decision-making for prostate cancer patients prior to surgery. Today there is a new report on the potential of positron emission tomography (PET) compared to MRI in a similar (but not precisely the same) situation.
Filed under: Diagnosis, Management, Risk | Tagged: MRI, PET, positrom emission spectroscopy, work-up | Leave a Comment »
One of the problems of first-line radiation therapy is how to treat patients with a rising PSA (biochemical relapse) after it becomes clear that the rise in PSA is not simply a “biochemical bounce” in the PSA.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: cryotherapy, outcome, prognosis, salvage | Leave a Comment »
Apparently the Centers for Medicare and Medicaid Services (CMS) rescinded the “least costly alternative” policy on April 19 this year.
Filed under: Living with Prostate Cancer | Tagged: LCA, least costly alternative, policy | Leave a Comment »
Data presented last week at the annual meeting of the American Roentgen Ray Society suggest that preoperative, endorectal magnetic resonance imaging (eMRI) of the prostate may help urologic surgeons to make decisions about whether to carry out nerve-sparing or non-nerve-sparing surgery in patients with prostate cancer.
Filed under: Management, Treatment | Tagged: endorectal, MRI, preoperative, prostatectomy, RALP | 1 Comment »
A new article in Cancer Prevention Research not only suggests the possibility that there is a very real association between selenium levels in serum after all, but it also helps to explain why this association may not have shown up in the large, double-blind, and randomized SELECT trial.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: genetics, risk, selenium | 1 Comment »
Whether we like it or not, there are significant costs associated with the diagnosis and management of prostate cancer over time. And there are very few good data (to date) on the relative costs associated with differing types of treatment over time.
Filed under: Living with Prostate Cancer | Tagged: cost, Medicare | 2 Comments »
A new report has suggested that, for men treated with intermittent androgen deprivation therapy (ADT) after biochemical relapse following surgery or radiation, the length of the first time-period off androgen deprivation therapy (ADT) may correlate with time to onset of castration-resistant prostate cancer (CRPC) and prostate cancer-specific mortality.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, castrration-resistant, CRPC, intermittent, survival | 1 Comment »
There is an increasing range of evidence to suggest that men who are on long-term statin therapy (with drugs like simvastatin, atorvastatin/Lipitor, or rosuvastatin/Crestor) are at lower risk for prostate cancer and do better than average in terms of treatment outcome if they are diagnosed with prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: EBRT, external beam radiation therapy, outcome, statin | 6 Comments »
In 2008, Vickers et al. initially proposed that a panel of four kallikrein markers, together with patient age, could potentially reduce the need for unnecessary biopsies in previously untested men with an elevated PSA level and a theoretical risk for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: early detection, kallikrein, PSA | 2 Comments »
In today’s news reports we address data from studies dealing with: Cancer risk in young Korean males with an elevated PSA level Mushroom-based supplements in the treatment of prostate cancer Outcomes after brachytherapy in intermediate-risk Canadian patients Traumatic stress among African American prostate cancer patients
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: African American, biopsy, brachytherapy, intermediate risk, outcome, risk, stress, Treatment, young men | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site